Janumet | Sitagliptin & metformin
Drug Class: DPP-4 Inhibitor
Approval Date: March 2007
Janumet is a combination of Januvia (sitagliptin) and metformin. Januvia reduces blood glucose by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4) while metformin reduces blood glucose by increasing the sensitivity of muscle, liver, fat and other tissues to insulin.
What does Janumet treat
Janumet is used for treating type 2 diabetes in combination with diet and exercise. It is not used for treating type 1 diabetes.
How Effective is Janumet
Janumet 50/1000 mg reduced hemoglobin A1C by 1.9% after 24 weeks while A1C increased by 0.2% in the placebo group.
66% of individuals treated with Janumet 50/1000 mg achieved A1C less than 7%. Only 20% and 23% of individuals treated with sitagliptin or metformin alone achieved A1C less than 7%.
What are interesting facts about Janumet
How is Janumet dosed and administered
Janumet is administered orally twice a day with meals. The maximum daily dose is 100/2000 mg.
What are the side effects of Janumet
Common: Abdominal pain, nausea, diarrhea, vomiting, weakness, headache, runny nose, sore throat, upper respiratory infection.
Serious: Lactic acidosis, pancreatitis, hypoglycemia (when combined with insulin or sulfonylurea).
How to obtain prescription assistance for Janumet
Contact the Janumet Prescription Assistance program.
References: Janumet FDA Prescribing Information
The material on this site is for information only and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
Comment on this article or post an article by joining the RxEconsult community.
Please Share on Your Social Networks